CO6690765A2 - Profármacos que comprenden un conjugado de conector de exendina - Google Patents

Profármacos que comprenden un conjugado de conector de exendina

Info

Publication number
CO6690765A2
CO6690765A2 CO13050270A CO13050270A CO6690765A2 CO 6690765 A2 CO6690765 A2 CO 6690765A2 CO 13050270 A CO13050270 A CO 13050270A CO 13050270 A CO13050270 A CO 13050270A CO 6690765 A2 CO6690765 A2 CO 6690765A2
Authority
CO
Colombia
Prior art keywords
exendin
prodrugs
conjugate
moiety
connector conjugate
Prior art date
Application number
CO13050270A
Other languages
English (en)
Inventor
Felix Cleemann
Ulrich Hersel
Torben Lessmann
Harald Rau
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of CO6690765A2 publication Critical patent/CO6690765A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Abstract

La presente invención se refiere a un profármaco o una sal del mismo farmacéuticamente aceptable, que comprende un conjugado de exendina-conector D-L, en el que D representa un resto de exendina; y -L es un resto conector que no es biológicamente activo -Lrepresentado por la fórmula (I),en la que la línea de trazos indica la unión a uno de los grupos amino del resto de exendina formando un enlace amida. La invención se refiere además a composiciones farmacéuticas que comprenden dichos profármacos así como a su uso como un medicamento para tratar o prevenir enfermedades o trastornos que se pueden tratar mediante la exendina.
CO13050270A 2010-09-17 2013-03-13 Profármacos que comprenden un conjugado de conector de exendina CO6690765A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10177327A EP2438930A1 (en) 2010-09-17 2010-09-17 Prodrugs comprising an exendin linker conjugate

Publications (1)

Publication Number Publication Date
CO6690765A2 true CO6690765A2 (es) 2013-06-17

Family

ID=43446651

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13050270A CO6690765A2 (es) 2010-09-17 2013-03-13 Profármacos que comprenden un conjugado de conector de exendina

Country Status (29)

Country Link
US (1) US9133276B2 (es)
EP (2) EP2438930A1 (es)
JP (1) JP5932796B2 (es)
KR (1) KR20130106820A (es)
CN (1) CN103237561B (es)
AR (1) AR082995A1 (es)
AU (1) AU2011303823B2 (es)
BR (1) BR112013006340A2 (es)
CA (1) CA2811352C (es)
CL (1) CL2013000716A1 (es)
CO (1) CO6690765A2 (es)
CY (1) CY1122226T1 (es)
DK (1) DK2616102T3 (es)
ES (1) ES2733734T3 (es)
HR (1) HRP20191128T1 (es)
HU (1) HUE044079T2 (es)
IL (1) IL225127A (es)
LT (1) LT2616102T (es)
MA (1) MA34517B1 (es)
MX (1) MX348983B (es)
MY (1) MY158974A (es)
NZ (1) NZ608387A (es)
PL (1) PL2616102T3 (es)
PT (1) PT2616102T (es)
RU (1) RU2593774C2 (es)
SG (1) SG188197A1 (es)
SI (1) SI2616102T1 (es)
UY (1) UY33605A (es)
WO (1) WO2012035139A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0507875B8 (pt) * 2004-03-23 2021-05-25 Complex Biosystems Gmbh pró-fármaco de cascata polimérico
SI2237799T1 (sl) * 2008-02-01 2019-07-31 Ascendis Pharma A/S Predzdravilo, ki obsega samo-cepljiv linker
DK2459171T3 (en) 2009-07-31 2017-09-25 Sanofi Aventis Deutschland Long-acting insulin composition
SI2459220T1 (sl) * 2009-07-31 2020-12-31 Ascendis Pharma A/S Biorazgradljivi v vodi netopni hidrogeli na osnovi polietilenglikola
BR112012002168A2 (pt) 2009-07-31 2016-05-31 Sanofi Aventis Deutschland profármacos compreendendo um conjugado ligador de insulina
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
AU2012322917B2 (en) * 2011-10-12 2016-11-03 Ascendis Pharma Ophthalmology Division A/S Prevention and treatment of ocular conditions
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366691A1 (en) 2012-12-21 2015-07-09 Sanofi Exendin-4 derivatives
WO2015081891A1 (en) * 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
CN104945499B (zh) * 2014-03-31 2019-12-10 博瑞生物医药（苏州）股份有限公司 结构修饰的glp-1类似物及其制备方法
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN106554403B (zh) * 2015-09-25 2021-08-31 博瑞生物医药（苏州）股份有限公司 艾塞那肽修饰物及其用途
MY196308A (en) 2016-03-01 2023-03-24 Ascendis Pharma Bone Diseases As PTH Prodrugs
EP4218795A3 (en) 2016-09-29 2023-08-30 Ascendis Pharma Bone Diseases A/S Pth compounds with low peak-to-trough ratios
AU2017336249A1 (en) 2016-09-29 2019-03-21 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release PTH compound
AR110299A1 (es) * 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
EP3335695B1 (en) * 2016-12-15 2020-02-05 UPM-Kymmene Corporation A method for freeze-drying hydrogel comprising nanofibrillar cellulose, a freeze-dried medical hydrogel comprising nanofibrillar cellulose, and a hydrogel comprising nanofibrillar cellulose
TWI783890B (zh) 2017-08-24 2022-11-11 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
UY38249A (es) 2018-05-30 2019-12-31 Sanofi Sa Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico
US20220181034A1 (en) * 2018-09-19 2022-06-09 Georgia Tech Research Corporation Self-titrating bacterial protease-activated prodrug
KR20220143037A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 Glp-1 조성물 및 이의 용도

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
AU641631B2 (en) 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
US5634943A (en) 1990-07-12 1997-06-03 University Of Miami Injectable polyethylene oxide gel implant and method for production
CA2117588C (en) 1992-02-28 1998-08-25 Jeffrey A. Hubbell Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE19626762A1 (de) 1996-07-03 1998-01-08 Basf Ag Enzymatisch spaltbare Linker für Festphasensynthesen
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
RU2200161C2 (ru) 1996-12-31 2003-03-10 Др. Редди'З Рисерч Фаундейшн Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
DK1032587T4 (da) 1997-11-14 2013-04-08 Amylin Pharmaceuticals Llc Hidtil ukendte exendinagonist-forbindelser
JP2003522721A (ja) 1997-11-14 2003-07-29 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンジンアゴニスト化合物
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
CA2312975C (en) 1997-12-17 2012-08-21 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
ATE255422T1 (de) 1998-01-07 2003-12-15 Debio Rech Pharma Sa Abbaubare, heterobifunktionelle polyethylenglykolacrylate, sowie damit herstellbare gele und konjugate
ATE366115T1 (de) 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc Inotropische und diuretische effekte von exendin und glp-1
AU6419899A (en) 1998-10-09 2000-05-01 Regents Of The University Of Michigan, The Hydrogels and water soluble polymeric carriers for drug delivery
WO2000033764A1 (en) 1998-12-04 2000-06-15 Pathak Chandrashekhar P Biocompatible crosslinked polymers
CA2356706C (en) * 1999-01-14 2014-09-30 Amylin Pharmaceuticals, Inc. Novel exendin agonist formulations and methods of administration thereof
AU773914B2 (en) 1999-02-01 2004-06-10 Eidgenossische Technische Hochschule Zurich Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
EP1591453A1 (en) 1999-05-17 2005-11-02 ConjuChem Inc. Modified peptides yy and conjugates thereof
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
JP2003503367A (ja) 1999-06-11 2003-01-28 シアウォーター・コーポレイション キトサンとポリ（エチレングリコール）または関連ポリマーから得られるヒドロゲル
US6372813B1 (en) 1999-06-25 2002-04-16 Motorola Methods and compositions for attachment of biomolecules to solid supports, hydrogels, and hydrogel arrays
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
WO2001055360A1 (en) 2000-01-28 2001-08-02 Infimed Therapeutics, Inc. Slow release protein polymers
US6884778B2 (en) 2000-04-14 2005-04-26 William Marsh Rice University Biocompatible macromers
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
JP4841066B2 (ja) 2000-09-01 2011-12-21 ライスユニバーシティ 酸化窒素生成ヒドロゲル物質
US6537569B2 (en) 2001-02-14 2003-03-25 Microvention, Inc. Radiation cross-linked hydrogels
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
EP1423093A4 (en) 2001-04-23 2005-11-30 Wisconsin Alumni Res Found BIFUNCTIONAL MODIFIED HYDROGEL
AP1763A (en) 2001-05-21 2007-08-02 Nektar Therapeutics Pulmonary administration of chemically modified insulin
DE60132094T3 (de) 2001-10-26 2012-02-02 Octoplus Polyactive Sciences B.V. Verfahren zur Herstellung von gereinigten Partikeln
US6960298B2 (en) 2001-12-10 2005-11-01 Nanogen, Inc. Mesoporous permeation layers for use on active electronic matrix devices
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
WO2003084926A2 (en) 2002-04-04 2003-10-16 Enzon, Inc. Polymeric acyl derivatives of indoles
DE10221457A1 (de) 2002-05-15 2003-11-27 Behr Gmbh & Co Wärmeübertrager und Verfahren zu seiner Herstellung
AU2003273272A1 (en) 2002-06-03 2003-12-19 Alinis Biosciences, Inc. Therapeutic agent-containing polymeric nanoarticles
CA2487077A1 (en) 2002-06-10 2003-12-18 Merck & Co., Inc. Isolated nucleic acid molecule encoding a novel centromere-associated motor protein, and uses thereof
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
EP1560599A1 (en) 2002-11-14 2005-08-10 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
SI1620118T1 (sl) 2003-04-08 2014-11-28 Yeda Research And Development Co., Ltd. Reverzibilna pegilirana zdravila
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
BRPI0507875B8 (pt) 2004-03-23 2021-05-25 Complex Biosystems Gmbh pró-fármaco de cascata polimérico
EP1586334A1 (en) 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
WO2006038462A1 (ja) 2004-10-01 2006-04-13 Kyushu University, National University Corporation 新規ステロイド産生細胞
DE102004051715A1 (de) 2004-10-23 2005-06-30 Clariant Gmbh Flüssigwaschmittel enthaltend Farbfixiermittel
US7678551B2 (en) 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US20060115865A1 (en) 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs
US7407117B2 (en) 2004-10-28 2008-08-05 Meadwestvaco Calmar, Inc. Liquid sprayer assembly
JP2006163996A (ja) 2004-12-09 2006-06-22 Evolium Sas 行動履歴に基づくプッシュ型の情報提供システム
EP1838317A4 (en) 2005-01-05 2012-02-29 Univ Minnesota ANALGESIC CONJUGATES
KR100665672B1 (ko) 2005-04-13 2007-01-09 성균관대학교산학협력단 새로운 온도 및 ｐＨ 민감성 블록 공중합체 및 이를 이용한고분자 하이드로겔
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
WO2007082088A2 (en) 2006-01-12 2007-07-19 Histogenics Corporation Method for repair and reconstruction of ruptured ligaments or tendons and for treatment of ligament and tendon injuries
EP1840152B1 (en) 2006-03-31 2009-07-08 Sony Deutschland Gmbh A method of forming a crosslinked polymer gel
WO2007140312A2 (en) 2006-05-25 2007-12-06 The General Hospital Corporation Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations
US20090306337A1 (en) 2006-07-31 2009-12-10 Novo Nordisk A/S Pegylated, Extended Insulins
KR20090055623A (ko) 2006-09-15 2009-06-02 엔존 파마슈티컬즈, 인코포레이티드 올리고뉴클레오티드 전달을 위한 방해된 에스테르 기재 생분해성 링커
AU2008214319A1 (en) * 2007-02-06 2008-08-14 Incept, Llc Polymerization with precipitation of proteins for elution in physiological solution
US20080220047A1 (en) 2007-03-05 2008-09-11 Sawhney Amarpreet S Low-swelling biocompatible hydrogels
WO2008116913A2 (en) 2007-03-28 2008-10-02 Novo Nordisk A/S Peptide compounds with transient biodegradable pegylation
EP2537539B1 (en) 2007-04-13 2019-04-03 Kuros Biosurgery AG Polymeric Tissue Sealant
WO2008148839A2 (en) * 2007-06-08 2008-12-11 Ascendis Pharma As Long-acting polymeric prodrugs of exendin
EP2170945A1 (en) 2007-07-16 2010-04-07 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
SI2237799T1 (sl) 2008-02-01 2019-07-31 Ascendis Pharma A/S Predzdravilo, ki obsega samo-cepljiv linker
AU2009214615B2 (en) 2008-02-13 2014-06-12 Hyperbranch Medical Technology, Inc. Crosslinked polyalkyleneimine hydrogels with tunable degradation rates
JP2011518881A (ja) 2008-04-28 2011-06-30 ゾゲニクス インコーポレーティッド 片頭痛の治療のための製剤
CA2721947C (en) 2008-04-29 2016-03-08 Ascendis Pharma As Pegylated recombinant human growth hormone compounds
AU2010220324A1 (en) 2009-03-05 2011-09-01 Ascendis Pharma As Interferon alpha carrier prodrugs
SI2459220T1 (sl) 2009-07-31 2020-12-31 Ascendis Pharma A/S Biorazgradljivi v vodi netopni hidrogeli na osnovi polietilenglikola
DK2459171T3 (en) 2009-07-31 2017-09-25 Sanofi Aventis Deutschland Long-acting insulin composition
BR112012002168A2 (pt) 2009-07-31 2016-05-31 Sanofi Aventis Deutschland profármacos compreendendo um conjugado ligador de insulina
JP5893566B2 (ja) 2009-10-29 2016-03-23 アセンディス ファーマ エー／エス 生分解性ヒドロゲルの滅菌
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate

Also Published As

Publication number Publication date
CY1122226T1 (el) 2020-11-25
CN103237561A (zh) 2013-08-07
MX348983B (es) 2017-07-06
HRP20191128T1 (hr) 2019-09-20
PT2616102T (pt) 2019-08-01
CL2013000716A1 (es) 2013-08-09
HUE044079T2 (hu) 2019-09-30
CA2811352A1 (en) 2012-03-22
US9133276B2 (en) 2015-09-15
EP2616102A1 (en) 2013-07-24
AR082995A1 (es) 2013-01-23
US20130189328A1 (en) 2013-07-25
RU2593774C2 (ru) 2016-08-10
EP2616102B1 (en) 2019-05-01
EP2438930A1 (en) 2012-04-11
UY33605A (es) 2012-04-30
PL2616102T3 (pl) 2019-10-31
LT2616102T (lt) 2019-07-25
BR112013006340A2 (pt) 2020-08-04
JP5932796B2 (ja) 2016-06-08
SG188197A1 (en) 2013-04-30
AU2011303823A1 (en) 2013-04-04
RU2013117441A (ru) 2014-10-27
CA2811352C (en) 2019-01-29
AU2011303823B2 (en) 2014-07-17
DK2616102T3 (da) 2019-07-29
IL225127A (en) 2017-07-31
ES2733734T3 (es) 2019-12-02
KR20130106820A (ko) 2013-09-30
NZ608387A (en) 2015-04-24
MX2013002822A (es) 2013-04-05
MY158974A (en) 2016-11-30
MA34517B1 (fr) 2013-09-02
CN103237561B (zh) 2015-12-02
JP2013538224A (ja) 2013-10-10
SI2616102T1 (sl) 2019-08-30
WO2012035139A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
CO6690765A2 (es) Profármacos que comprenden un conjugado de conector de exendina
CO6491083A2 (es) Profarmacos que comprenden un conugado de insulina-conector
AR105319A1 (es) Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
CO2019006912A2 (es) Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico
CR20120237A (es) Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos
ECSP11011561A (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
CR20110255A (es) Nuevos compuestos 578
EA201792071A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
BR112013012665A2 (pt) composto de fórmula (i), ou um sal, pró-droga ou solvato do mesmo e composição farmacêutica
UY33279A (es) Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2
ECSP12011632A (es) Profármacos que comprenden un conjugado de insulina-conector
CU20120074A7 (es) Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos